Logo image of LAB.CA

LABRADOR GOLD CORP (LAB.CA) Stock Fundamental Analysis

TSX-V:LAB - TSX Venture Exchange - CA50543R1091 - Common Stock - Currency: CAD

0.115  +0.01 (+4.55%)

Fundamental Rating

2

LAB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 806 industry peers in the Metals & Mining industry. While LAB has a great health rating, there are worries on its profitability. LAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LAB has reported negative net income.
LAB had a negative operating cash flow in the past year.
LAB had negative earnings in each of the past 5 years.
LAB had a negative operating cash flow in each of the past 5 years.
LAB.CA Yearly Net Income VS EBIT VS OCF VS FCFLAB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -82.91%, LAB is doing worse than 72.21% of the companies in the same industry.
LAB's Return On Equity of -83.26% is on the low side compared to the rest of the industry. LAB is outperformed by 63.52% of its industry peers.
Industry RankSector Rank
ROA -82.91%
ROE -83.26%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LAB.CA Yearly ROA, ROE, ROICLAB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

LAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LAB.CA Yearly Profit, Operating, Gross MarginsLAB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

LAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LAB.CA Yearly Shares OutstandingLAB.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
LAB.CA Yearly Total Debt VS Total AssetsLAB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

LAB has an Altman-Z score of 100.66. This indicates that LAB is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 100.66, LAB belongs to the best of the industry, outperforming 94.04% of the companies in the same industry.
LAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 100.66
ROIC/WACCN/A
WACCN/A
LAB.CA Yearly LT Debt VS Equity VS FCFLAB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 177.33 indicates that LAB has no problem at all paying its short term obligations.
LAB's Current ratio of 177.33 is amongst the best of the industry. LAB outperforms 99.50% of its industry peers.
A Quick Ratio of 177.33 indicates that LAB has no problem at all paying its short term obligations.
LAB has a better Quick ratio (177.33) than 99.50% of its industry peers.
Industry RankSector Rank
Current Ratio 177.33
Quick Ratio 177.33
LAB.CA Yearly Current Assets VS Current LiabilitesLAB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LAB have decreased strongly by -3073.17% in the last year.
EPS 1Y (TTM)-3073.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5500%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LAB.CA Yearly EPS VS EstimatesLAB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -0 -0 -0.01 -0.01 -0.01

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB.CA Price Earnings VS Forward Price EarningsLAB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB.CA Per share dataLAB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 -0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LABRADOR GOLD CORP

TSX-V:LAB (7/30/2025, 7:00:00 PM)

0.115

+0.01 (+4.55%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)01-24 2025-01-24
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.66%
Ins Owner ChangeN/A
Market Cap19.55M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.91%
ROE -83.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17921%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 177.33
Quick Ratio 177.33
Altman-Z 100.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)73351%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3073.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5500%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.31%
OCF growth 3YN/A
OCF growth 5YN/A